223 related articles for article (PubMed ID: 18684227)
1. Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.
Chen W; Wang LL; Liu HY; Long L; Li S
Basic Clin Pharmacol Toxicol; 2008 Sep; 103(3):240-6. PubMed ID: 18684227
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.
Risérus U; Sprecher D; Johnson T; Olson E; Hirschberg S; Liu A; Fang Z; Hegde P; Richards D; Sarov-Blat L; Strum JC; Basu S; Cheeseman J; Fielding BA; Humphreys SM; Danoff T; Moore NR; Murgatroyd P; O'Rahilly S; Sutton P; Willson T; Hassall D; Frayn KN; Karpe F
Diabetes; 2008 Feb; 57(2):332-9. PubMed ID: 18024853
[TBL] [Abstract][Full Text] [Related]
3. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
Luquet S; Lopez-Soriano J; Holst D; Gaudel C; Jehl-Pietri C; Fredenrich A; Grimaldi PA
Biochimie; 2004 Nov; 86(11):833-7. PubMed ID: 15589693
[TBL] [Abstract][Full Text] [Related]
4. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Olson EJ; Pearce GL; Jones NP; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
[TBL] [Abstract][Full Text] [Related]
5. Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.
Coll T; Alvarez-Guardia D; Barroso E; Gómez-Foix AM; Palomer X; Laguna JC; Vázquez-Carrera M
Endocrinology; 2010 Apr; 151(4):1560-9. PubMed ID: 20185762
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.
Yin Y; Russell RG; Dettin LE; Bai R; Wei ZL; Kozikowski AP; Kopelovich L; Glazer RI
Cancer Res; 2005 May; 65(9):3950-7. PubMed ID: 15867396
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.
Bojic LA; Burke AC; Chhoker SS; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Tirona RG; Yin H; Pickering JG; Huff MW
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):52-60. PubMed ID: 24158519
[TBL] [Abstract][Full Text] [Related]
8. Treatment with PPARδ agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model.
Li X; Li J; Lu X; Ma H; Shi H; Li H; Xie D; Dong L; Liang C
Int J Mol Med; 2015 Sep; 36(3):767-75. PubMed ID: 26133486
[TBL] [Abstract][Full Text] [Related]
9. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
[TBL] [Abstract][Full Text] [Related]
10. A new, highly selective murine peroxisome proliferator-activated receptor δ agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice.
Ngala RA; Stocker CJ; Roy AG; Hislop D; Wargent E; Bell R; Hassall DG; Harling JD; Billin AN; Willson TM; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2011 May; 13(5):455-64. PubMed ID: 21272187
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P
J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894
[TBL] [Abstract][Full Text] [Related]
12. In vitro responsiveness of human muscle cell peroxisome proliferator-activated receptor δ reflects donors' insulin sensitivity in vivo.
Ordelheide AM; Heni M; Thamer C; Machicao F; Fritsche A; Stefan N; Häring HU; Staiger H
Eur J Clin Invest; 2011 Dec; 41(12):1323-9. PubMed ID: 21615395
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.
Iwashita A; Muramatsu Y; Yamazaki T; Muramoto M; Kita Y; Yamazaki S; Mihara K; Moriguchi A; Matsuoka N
J Pharmacol Exp Ther; 2007 Mar; 320(3):1087-96. PubMed ID: 17167170
[TBL] [Abstract][Full Text] [Related]
14. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
Tsunoda M; Kobayashi N; Ide T; Utsumi M; Nagasawa M; Murakami K
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E833-40. PubMed ID: 18212024
[TBL] [Abstract][Full Text] [Related]
15. Intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia.
Doktorova M; Zwarts I; Zutphen TV; Dijk THV; Bloks VW; Harkema L; Bruin A; Downes M; Evans RM; Verkade HJ; Jonker JW
Sci Rep; 2017 Apr; 7(1):846. PubMed ID: 28404991
[TBL] [Abstract][Full Text] [Related]
16. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.
Jucker BM; Yang D; Casey WM; Olzinski AR; Williams C; Lenhard SC; Legos JJ; Hawk CT; Sarkar SK; Newsholme SJ
Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1256-64. PubMed ID: 17726146
[TBL] [Abstract][Full Text] [Related]
17. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
Nagasawa T; Inada Y; Nakano S; Tamura T; Takahashi T; Maruyama K; Yamazaki Y; Kuroda J; Shibata N
Eur J Pharmacol; 2006 Apr; 536(1-2):182-91. PubMed ID: 16574099
[TBL] [Abstract][Full Text] [Related]
18. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
[TBL] [Abstract][Full Text] [Related]
19. Regulatory role of peroxisome proliferator-activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment?
Grimaldi PA
Biochimie; 2005 Jan; 87(1):5-8. PubMed ID: 15733729
[TBL] [Abstract][Full Text] [Related]
20. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.
Chen Y; Li Y; Wang Y; Wen Y; Sun C
Metabolism; 2009 Dec; 58(12):1694-702. PubMed ID: 19767038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
